SCHEMBL1285358

SCHEMBL1285358

Cc1cc(O)cc2oc(=O)[nH]c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.45
NUAK1 O60285 2/20 0.45
IGF1R P08069 2/20 0.45
PIM1 P11309 2/20 0.45
SRC P12931 2/20 0.45
PLK1 P53350 2/20 0.45
PKN1 Q16512 2/20 0.45
AURKB Q96GD4 2/20 0.45
ALK Q9UM73 2/20 0.45
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
CASP1 P29466 2/20 0.42
CASP7 P55210 2/20 0.42
CA9 Q16790 2/20 0.42
HSD17B10 Q99714 2/20 0.42
CYP3A4 P08684 2/20 0.42
TSHR P16473 1/20 0.42
CLK2 P49760 1/20 0.41
NOS1 P29475 2/20 0.41
NOS3 P29474 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11132639 0.81 NOS1 (0.52) CA9HSD17B10TSHRNOS1NOS3
SCHEMBL1285628 0.78 NOS1 (0.41) HSD17B10TSHRNOS1NOS3NOS2
SCHEMBL15759798 0.78 NOS1 (0.44) HSD17B10TSHRNOS1NOS3NOS2
SCHEMBL520456 0.78 NOS1 (0.41) ALDH1A1HPGDCASP1CASP7CA9
SCHEMBL1285298 0.78 NOS1 (0.41) HSD17B10TSHRNOS1NOS3NOS2
SCHEMBL1700932 0.77 NOS1 (0.38) TSHRNOS1NOS3NOS2SYK
SCHEMBL29957729 0.77 NOS1 (0.38) TSHRNOS1NOS3NOS2SYK
SCHEMBL1286048 0.77 TTR (0.41) ALDH1A1HPGDHSD17B10NOS1NOS3
SCHEMBL1285709 0.77 CREBBP (0.41) ALDH1A1NOS1NOS3NOS2SYK
Hydrochloric Acid SCHEMBL1285729 0.76 SYK (0.39) TSHRNOS1NOS3NOS2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379529-B1 CGRP-ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2015-06-10 EP disclosed
EP-2379529-B1 CGRP-ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2015-06-10 EP disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-20120088755-A1 Novel Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-12 US disclosed
US-20120088755-A1 Novel Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-12 US disclosed
US-20120088755-A1 Novel Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-12 US disclosed
EP-2379529-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-26 EP disclosed
WO-2010070022-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-06-24 WO disclosed
WO-2010070022-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088755-A1 Novel Compounds SLC26A4, F12, SLCO1B3 KDR 4125/4885NUAK1 2484/4885IGF1R 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.